We are live on ! Find out more
EFM

E Fund Management Portfolio holdings

AUM $4.46B
This Fund
S&P 500
This Quarter Est. Return
+11.44%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.81B
AUM Growth
+$194M
Cap. Flow
+$40.5M
Cap. Flow %
2.24%
Top 10 Hldgs %
63.7%
Holding
392
New
24
Increased
176
Reduced
102
Closed
74

Top Buys

Rank Stock Value
1
FUTU icon
Futu Holdings
FUTU
+$32.5M
2
AMAT icon
Applied Materials
AMAT
+$26.5M
3
AAPL icon
Apple
AAPL
+$13.7M
4
MSFT icon
Microsoft
MSFT
+$11.9M
5
NVDA icon
NVIDIA
NVDA
+$9.49M

Top Sells

Rank Stock Value
1
AMD icon
Advanced Micro Devices
AMD
+$28.3M
2
BEKE icon
KE Holdings
BEKE
+$13.2M
3
TSM icon
TSMC
TSM
+$13.2M
4
ASX icon
ASE Group
ASX
+$7.59M
5
IQ icon
iQIYI
IQ
+$6.13M

Sector Composition

Rank Sector Weight
1 Consumer Discretionary 39.73%
2 Technology 31.74%
3 Communication Services 9.52%
4 Healthcare 5.08%
5 Financials 4.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IRWD icon
301
Ironwood Pharmaceuticals
IRWD
$682M
$152K 0.01%
23,342
-24,755
-51% -$175K
ARQT icon
302
Arcutis Biotherapeutics
ARQT
$2.99B
$147K 0.01%
15,759
-23,107
-59% -$209K
SANA icon
303
Sana Biotechnology
SANA
$1.18B
$113K 0.01%
20,675
-2,686
-11% -$21.4K
MNKD icon
304
MannKind Corp
MNKD
$1.27B
$111K 0.01%
21,279
-13,317
-38% -$60.4K
COGT icon
305
Cogent Biosciences
COGT
$6.02B
$94.2K 0.01%
11,173
-22,135
-66% -$168K
TVTX icon
306
Travere Therapeutics
TVTX
$6.19B
$91K 0.01%
11,071
-17,057
-61% -$115K
ALT icon
307
Altimmune
ALT
$605M
$89.5K ﹤0.01%
13,458
-28,251
-68% -$208K
CDMO
308
DELISTED
Avid Bioservices, Inc. Common Stock
CDMO
$79.9K ﹤0.01%
11,194
-13,643
-55% -$104K
SMMT icon
309
Summit Therapeutics
SMMT
$11B
$78.6K ﹤0.01%
10,076
-20,653
-67% -$112K
RLAY icon
310
Relay Therapeutics
RLAY
$4.11B
$76.8K ﹤0.01%
11,778
-10,152
-46% -$69.4K
OCGN icon
311
Ocugen
OCGN
$448M
$75K ﹤0.01%
+48,412
New +$75.4K
EDIT icon
312
Editas Medicine
EDIT
$485M
$60.9K ﹤0.01%
13,051
-25,031
-66% -$141K
SCLX icon
313
Scilex Holding
SCLX
$38.2M
$60.7K ﹤0.01%
898
– –
ALLO icon
314
Allogene Therapeutics
ALLO
$698M
$59K ﹤0.01%
25,333
-11,797
-32% -$34.8K
AVXL icon
315
Anavex Life Sciences
AVXL
$277M
$57.5K ﹤0.01%
13,623
-18,036
-57% -$73K
HRTX icon
316
Heron Therapeutics
HRTX
$62M
$54.7K ﹤0.01%
+15,642
New +$48.1K
CCCC icon
317
C4 Therapeutics
CCCC
$474M
$52.1K ﹤0.01%
11,280
-28,116
-71% -$168K
ZNTL icon
318
Zentalis Pharmaceuticals
ZNTL
$360M
$41.6K ﹤0.01%
10,177
-3,906
-28% -$43.6K
AKRO
319
DELISTED
Akero Therapeutics
AKRO
– –
-13,899
Closed -$351K
ALEC icon
320
Alector
ALEC
$261M
– –
-13,025
Closed -$78.4K
ALGN icon
321
Align Technology
ALGN
$11.2B
– –
-684
Closed -$224K
APGE icon
322
Apogee Therapeutics
APGE
$10.2B
– –
-3,125
Closed -$208K
ARCT icon
323
Arcturus Therapeutics
ARCT
$432M
– –
-7,400
Closed -$250K
AZO icon
324
AutoZone
AZO
$48.4B
– –
-255
Closed -$804K
BAX icon
325
Baxter International
BAX
$13.5B
– –
-4,788
Closed -$205K
11 12
13
14 15

Similar funds

ACM
Advent Capital Management New York $4.46B AUM 0.73% 1-Year Est. Return
HCM
Hamlin Capital Management New York $4.45B AUM 22.95% 1-Year Est. Return
MAM
Magellan Asset Management Sydney, Australia $4.47B AUM 4.2% 1-Year Est. Return
AP
Americana Partners Houston, Texas $4.44B AUM 29.45% 1-Year Est. Return
BP
BC Partners New York $4.43B AUM 49.12% 1-Year Est. Return
WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.48B AUM 24.77% 1-Year Est. Return
AOI
Auto-Owners Insurance Lansing, Michigan $4.43B AUM 30.05% 1-Year Est. Return
WA
WestEnd Advisors Charlotte, North Carolina $4.49B AUM 19.44% 1-Year Est. Return

E Fund Management's Q2 2024 Portfolio in Review

As of Q2 2024, E Fund Management held 392 positions worth $1.81B, up 12% from $1.61B the previous quarter. Its ten largest holdings account for 64% of the portfolio.

E Fund Management's Q2 2024 filing shows 24 new, 176 increased, 102 reduced and 74 closed positions. Its largest new stake was Futu Holdings: 480,000 shares worth $31.5M. The largest sale was Advanced Micro Devices, an estimated $28.3M.

By sector, the portfolio is most concentrated in Consumer Discretionary at 40% of assets, down from 40% a quarter earlier, followed by Technology and Communication Services.

  • E Fund Management's largest Q2 2024 buy was Futu Holdings: 480,000 shares worth $31.5M.
  • E Fund Management added most to Applied Materials in Q2 2024, an estimated $26.5M increase.
  • E Fund Management's biggest Q2 2024 reduction was Advanced Micro Devices, cutting an estimated $28.3M.
  • E Fund Management fully exited Yum China in Q2 2024, selling an estimated $5.17M.
  • E Fund Management's ten largest holdings make up 64% of its $1.81B portfolio in Q2 2024.
  • E Fund Management opened 24 new positions and closed 74 in Q2 2024.
  • E Fund Management's portfolio value rose 12% quarter-over-quarter to $1.81B.

Based on E Fund Management's 13F filing for Q2 2024, filed 12 Aug 2024.